Combination of epitopes and use thereof, vaccine construct, method for inducing immune response, and method for identifying epitopes

By identifying and combining the T cell epitope of SARS-CoV-2, a vaccine construct that binds multiple HLA-DR molecules was designed to solve the problems of low vaccination coverage and insufficient antigenicity in the global vaccine, and achieved the Efficient, lasting immune response to COVID-19 and effective protection of new variants.

CN118984833APending Publication Date: 2024-11-19ZERBINI FOUNDATION
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380029886.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-25
Filing Date
2023-03-24
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing COVID-19 vaccine has low vaccination coverage worldwide, making it difficult to induce a lasting cellular immune response, especially in low- and middle-income countries and remote areas, and faces challenges brought by new variants, and existing technologies are difficult to provide. Enough antigenicity and immunogenicity.

Method used

By identifying and combining at least 8 T cell epitopes of SARS-CoV-2, combining multiple HLA-DR molecules, a vaccine construct containing RBD monomers or dimers is designed to induce CD4+ and CD8+ T The immune response of cells improves vaccine coverage and antigenicity.

Benefits of technology

A high coverage T cell response to most populations was achieved, which enhanced the immune response to SARS-CoV-2 virus, improved the antigenicity and durability of the vaccine, and reduced sensitivity to new variants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984833A_ABST
    Figure CN118984833A_ABST
Patent Text Reader

Abstract

Combinations of epitopes and uses thereof, vaccine constructs, methods of inducing an immune response, methods of identifying epitopes. The present invention relates to an epitope combination comprising at least 8 T cell epitopes from SARS-CoV-2 and the use of said combination ("epitope group"). The epitope is widely recognized by CD4 + T lymphocytes of most of individuals in the COVID-19 convalescence phase.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to new epitopes used in combination and recognized by CD4+ T lymphocytes. In addition, the present invention relates to the use of such epitopes and combinations thereof, in particular for the treatment or prevention of diseases caused by the SARS-CoV-2 virus.

[0002] Furthermore, the present invention relates to methods for identifying epitopes for use in combination and to methods for preventing infections caused by SARS-CoV-2.

[0003] Specifically, the present invention relates to a combination of at least 8 T cell epitopes from SARS-CoV-2 in a construct having a SARS-CoV-2 spike protein receptor binding domain (RBD) monomer or dimer.

[0004] In addition, the present invention can be used to induce enhanced T cell responses to COVID-19 vaccine antigens and breakthrough infections. Therefore, the present invention also describes the use of the combination for the production of a vaccine. Background Art

[0005] Although vaccines against Covid-19 have been used as an important measure to respond to the Covid-19 pandemic, there is a general recognition in society around the world that the vaccines currently in use are not sufficient to eradicate the virus or even to prevent reinfection or transmission.

[0006] In addition, the world has faced further challenges in the Covid-19 pandemic since vaccination began in late 2021. Manufacturing, purchasing and distributing to achieve global coverage remains a daunting logistical and financial task, especially in low- and middle-income countries and remote areas. As a result, the uneven distribution of vaccines among countries has led to low vaccination coverage, far from the proportion of the immune population required to control the pandemic, which has also contributed to the emergence of new variants.

[0007] Therefore, there is still an urgent need for vaccines that can induce better immune responses against the SARS-CoV-2 virus that are reliable, low-cost, easy to handle and store, but most importantly, highly antigenic / immunogenic, including better cellular (T cell-mediated) immune responses that are more durable than antibodies in coronavirus infection.

[0008] Documents that have been published in the prior art attempt to provide technical solutions in terms of immune response to control the Covid-19 pandemic.

[0009] Document WO2021195286 discloses compositions and methods for treating and preventing coronavirus using RBD polypeptides.

[0010] Document IN202011018845 discloses a codon-optimized nucleotide sequence designed to express the RBD of the SARS-CoV-2 spike protein. The technical solution described in this document is aimed at identifying small molecules or peptides with antiviral potential to develop antigen-antibody-based diagnostic tests and discover and validate antibodies against SARS-CoV-2 RBD.

[0011] None of these documents provide the technical solution.

[0012] Therefore, an object of the present invention is to provide a vaccine construct that induces a better cellular immune response.

[0013] To achieve the above objectives, it is necessary to identify a set of SARS-CoV-2 T cell epitopes with broad population coverage, which, when bound to the monomeric or dimeric RBD of the spike protein of the SARS-CoV-2 virus, can induce higher cellular immune responses in all populations exposed to the virus.

[0014] The identification of such immunodominant peptides is not obvious. Furthermore, given the nature of T cell epitope recognition, it is unlikely that a single T cell epitope will be recognized by all individuals. Therefore, it is necessary to use a combination of immunodominant T cell epitopes to maximize the coverage of the vaccine.

[0015] According to computer simulation analysis, the increase in the number of epitopes will allow each HLA-DRB1 and each individual to recognize a greater number of peptides, and when the complete peptide set of SEQ ID NO: 1 to 19 is used, each HLA-DRB1 can reach a minimum of 10 peptides. The increase in the number of epitopes recognized by each individual will increase the amplitude and coverage of vaccination. The more peptides each vaccinee recognizes, the more difficult it is for mutations to jeopardize vaccine-induced protection against new mutant viruses. Complete coverage with sufficient breadth (the number of T cell epitopes recognized by each individual) is an expected emerging property of the combination of promiscuous HLA-binding epitopes. In a genetically heterogeneous population, each epitope alone will never be as antigenic / immunogenic as a combination of promiscuous multiple HLA-DR binding single epitopes.

[0016] Therefore, the present invention discloses a technical solution, namely, identifying a group of SARS-CoV-2 peptides that can bind to multiple HLA class II molecules and using them in a vaccine construct against the SARS-CoV-2 virus.

[0017] Therefore, each individual will carry an HLA capable of presenting multiple such SARS-CoV2 peptides to T cells. This will allow the vast majority of the vaccinated population to generate T cell responses to multiple epitopes.

[0018] Furthermore, in vaccines, CD8+ T cell epitopes are critical for the destruction of virus-infected cells and help control subsequent infection or reinfection. An approach to identifying CD8+ T cell epitopes with broad population coverage is to look for peptides that stably bind to HLA class I molecules / alleles that cover the vast majority of the population.

[0019] According to the identification method of the present invention, several peptides can be identified, and the identification of these peptides is equivalent to hundreds of peptides taught in the prior art, but because the present invention uses a small number of peptides instead of hundreds of peptides, the required resources are much less.

[0020] Brief Description of Sequence Listing

[0021] The present invention will be more clearly understood upon reading the following non-limiting detailed description and the sequence listing provided herein. Summary of the invention

[0022] The present invention relates to an epitope combination comprising at least 8 T cell epitopes from SARS-CoV-2, and the use of the combination ("epitope group"). The epitopes are widely recognized by CD4+T lymphocytes of the vast majority of individuals in the recovery period of COVID-19.

[0023] Another object of the present invention is a vaccine construct comprising the amino acid sequence of a single polypeptide.

[0024] Furthermore, the present invention also embodies a method of inducing an immune response, comprising administering the vaccine construct.

[0025] Furthermore, the present invention relates to a method for identifying the optimal combination of SARS-CoV-2 T cell epitopes for a vaccine to achieve high coverage of the world population, comprising the following steps:

[0026] a) selecting peptides from the entire SARS-CoV-2 proteome sequence, wherein the peptides bind to at least 50% of the HLA-DR molecules in the bioinformatics server https: / / webs.iiitd.edu.in / raghava / propred / ;

[0027] b) extending the selected sequence of the peptide at the N-terminus and the C-terminus;

[0028] c) World population coverage study based on the frequencies of HLA molecules predicted to bind to peptides from the iedb.org website;

[0029] d) synthesizing the corresponding peptide;

[0030] e) Confirm and test SARS-CoV-2-specific responses in susceptible individuals who had mild COVID-19 illness (not hospitalized) and recovered well.

[0031] Another object of the present invention is the use of epitope groups / epitope combinations for the production of vaccine constructs using dimeric or monomeric RBDs of the SARS-CoV-2 viral spike protein. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 : Figure 1 is a chart showing the world population coverage of all 19 peptides based on the frequencies of HLA molecules predicted to bind to the peptides as assessed by IEDB population coverage on iedb.org. The results of the in silico analysis indicate that 99.6% of the world population can recognize at least one of the epitopes. The average hit rate means that on average each individual should recognize 29 HLA / epitope combinations. Pc90 means that 90% of the world population should recognize at least 15 HLA / epitope combinations.

[0033] Figure 2 : Figure 2 A whole blood cytokine secretion high-throughput T cell assay based on cytokine release using 19 SARS-CoV-2 CD4+ T cell epitopes of the present invention was shown. The results showed that 42 / 45 (94%) SARS-CoV-2 seropositive subjects showed peptide-induced cytokine secretion, indicating T cell recognition of T cell epitopes, while none of the 16 seronegative subjects showed a T cell response. This suggests that these peptides are specific to individuals in the COVID-19 recovery period.

[0034] Figure 3 : Figure 3 ROC curves are shown - IL-2 and IFN-γ production in whole blood in response to the SARS-CoV-2 epitopes of the present invention.

[0035] Figure 4 A / B: Figure 4 The dimeric RBD protein from the Wuhan strain is shown. Figure 5 A) Schematic diagram of the dimeric RBD protein. Figure 5 B) Map of the pcDNA3.1 plasmid containing the two tandem sequences of RBD.

[0036] Figure 5 A / B: Figure 5 Purification of dimeric RBD protein by nickel resin affinity chromatography is shown. Figure 5 A) Purification chromatogram using IMAC-Ni resin. Figure 5B) 7.5% SDS-PAGE gel under non-reducing conditions, containing the following different fractions: 1. Molecular weight markers; 2. Supernatant of pre-column dialysis; 3. Eluate after column loading; 4. Eluate after washing steps; 5. Eluate from elution fraction 1; 6. Eluate from elution fraction 2; 7. Eluate after column regeneration.

[0037] Figure 6 A / B: Figure 6 Purification of dimeric RBD protein by ion exchange is shown. Figure 6 A) Chromatogram of ion exchange purification on S-Sepharose with a salt gradient up to 500 mM. Figure 6 B) 7.5% SDS-PAGE gel under non-reducing conditions, containing the following different fractions: 1. supernatant of pre-column dialysis; 2. eluate after column loading; 3. eluate after washing steps; 4. molecular weight marker; 5. eluate from elution fraction 1; 6. eluate from elution fraction 2; 7. eluate from elution fraction 3; 8. eluate from elution fraction 4; 9. eluate from elution fraction 5; 10. eluate from elution fraction 6.

[0038] Figure 7 A / B: Figure 7 The stability of the dimeric RBD protein in the culture supernatant was shown. Figure 7 A) After waiting for 4 days, protein purification chromatography was performed using IMAC-Ni resin and 7.5% SDS-PAGE gel under non-reducing conditions, containing the following purified protein fractions: 1. Molecular weight marker (kDa); 2. Purified dimeric RBD protein. Figure 7 B) Chromatogram of protein purification using IMAC-Ni resin after waiting for 5 days and 7.5% SDS-PAGE gel under non-reducing conditions, containing the following purified protein fractions: 1. Molecular weight marker (kDa); 2. Purified dimeric RBD protein.

[0039] Figure 8 : Figure 8 Shown are ELIspot responses of PBMCs from convalescent SARS-CoV-2 patients 40 days after symptom onset to a pool of 19 CD4+ T cell epitopes.

[0040] Fig. 9 : Fig. 9 Shown are ELIspot responses of PBMCs from convalescent SARS-CoV-2 patients 40 days after symptom onset to a pool of 26 CD8+ T cell epitopes.

[0041] Fig.10 : Fig.10Anti-RBD titers in C57Bl / 6 mice immunized with recombinant Wuhan dimeric RBD or RBD+8 synthetic peptides encoding CD4+ T cell epitopes are shown.

[0042] Fig.11 : Fig.11 The cellular immune responses to single SARS-CoV-2 dipeptides in mice immunized with dimeric Wuhan RBD or dimeric Wuhan RBD + mixed SARS-CoV-2 dipeptides are shown.

[0043] Fig.12 : Fig.12 Cellular immune responses of mice are shown. The figure shows the measurement of cellular immune responses to RBD stimulation in different immunization groups (negative control (adjuvant), RBD, RBD+dipeptide). DETAILED DESCRIPTION

[0044] A series of literature data show that the main target of neutralizing antibodies against SARS-CoV2 virus is the spike protein (S). More specifically, antibodies with high neutralizing ability target the binding domain (receptor binding domain, RBD) of ACE2 receptor (angiotensin 2 converting enzyme). Therefore, the present invention uses RBD in vaccine constructs against Covid-19 infection.

[0045] Based on structure-guided design data showing that the dimeric form of RBD is more immunogenic than the monomeric form, a dimeric vaccine antigen was constructed using the strategy described by Dai et al. (2020) (DAI et al., 2020). In this strategy, two RBD sequences from the Wuhan strain (amino acids R319 to K537) ( Figure 4 A / B). To ensure the expression of recombinant protein, the signal peptide sequence of the gene encoding human IgE was added (YAN et al., 2007), and a 6-histidine (HisTag) sequence was added to the C-terminal part, which is necessary for the purification of vaccine antigens for preclinical testing ( Figure 4 A). The sequence was synthesized after codon optimization for expression in mammalian cells and cloned into the expression vector pcDNA3.1 from GenScript (Piscataway, USA) ( Figure 4 B).

[0046] The pcDNA3.1 plasmid containing the dimeric RBD sequence was recombined in ultrapure water and transformed into chemically competent Escherichia coli TOP-10 bacteria by heat shock. Figure 4As shown in B, the pcDNA3.1 plasmid has an ampicillin resistance gene for selecting transformed bacteria at a concentration of 100 μg / mL. The isolated colonies were inoculated into liquid Luria Bertani (LB) medium containing ampicillin and continuously shaken (~300 pm) for 16-18 hours at 37°C. Plasmid DNA was extracted using the PureLink HiPure Plasmid Maxiprep kit (Thermo Fisher Scientific). The quality of the obtained DNA was evaluated by optical spectrophotometry at 260 and 280 nm.

[0047] Plasmid DNA was transfected into Chinese hamster ovary cells (ExpiCHO-S) using the ExpiCHO™ Expression System Kit (Thermo Fisher Scientific), which contains different media and reagents for transfection.

[0048] Transient transfection was performed using ExpiFectamine CHO reagent and plasmid DNA, both of which were previously diluted in OptiPROSFM medium. The bottles were placed in a wet oven at 37°C and 8% CO2 partial pressure and shaken. 16 to 22 hours after transfection, the cultures received ExpiCHO Feed medium and ExpiFectamine CHO Enhancer, the oven temperature was changed to 32°C, the CO2 partial pressure was reduced to 5%, and the same shaking as the previous day. After 10 days of expression, the culture supernatant was clarified by centrifugation, followed by dialysis and purified by affinity chromatography on nickel resin (IMAC-Ni, Cytiva) or ion exchange using the cationic resin S-Sepharose (Cytiva).

[0049] Figure 5 A / B shows the purification chromatogram of dimeric RBD protein on IMAC-Ni column ( Figure 5 A), and 7.5% SDS-PAGE gel containing different fractions ( Figure 5 B). For this purification, the culture supernatant was dialyzed into 20 mM NaH2PO4, 500 mM NaCl and 50 mM imidazole buffer (pH 7.4). The IMAC-Ni column was equilibrated with the same buffer and the supernatant containing the dimeric RBD protein was loaded onto the column. The column was also washed with the same buffer and the protein was eluted with 20 mM NaH2PO4, 500 mM NaCl and 300 mM imidazole (pH 7.4). Figure 5As shown in B, the dimeric RBD protein eluted in elution fraction 1 (lane 5). After elution, the eluate was dialyzed and concentrated into PBS using an Amicon Ultra 10 MWCO (Merck Sigma).

[0050] The results of ion exchange purification of dimeric RBD protein are shown in Figure 6 As shown in A / B. In this case, the culture supernatant was dialyzed in a buffer containing 50 mM Tris-HCl (pH 7.4). The S-Sepharose column was equilibrated and washed with the same buffer. Elution was performed by a concentration gradient of 0 to 500 mM NaCl (pH 7.4). Figure 6 A). Figure 6 B shows a 7.5% SDS-PAGE gel containing the different fractions, and we can see that the dimeric RBD protein is successfully eluted between fractions 3 and 6 (lanes 7 to 10). In the same way as the affinity column elution, the different fractions containing the protein were pooled, dialyzed and concentrated into PBS using an Amicon Ultra 10 MWCO (Merck Sigma).

[0051] The dimeric RBD protein was further expressed at other times with consistent results. To test the stability of the protein in the culture supernatant, transient transfections were performed and the supernatant was then stored at 4°C for 4 or 5 days before dialysis and purification. Thereafter, the dimeric RBD protein was purified by nickel resin affinity chromatography as described above. Figure 7 A / B shows a 4-day wait ( Figure 7 A) and 5 days ( Figure 7 B) Chromatogram and 7.5% SDS-PAGE gel containing purified protein.

[0052] These results concluded that the dimeric RBD protein was stable in culture supernatants for at least 5 days at 4 °C before purification.

[0053] Thus, the present invention relates to a combination of at least 8 synthetic peptides, including the following sequences, either simple or with covalent modifications, such as myristoylation and other forms of lipopeptides, added terminal cysteines or other forms that may allow polymerization, referred to herein as epitopes, selected from the entire SARS-CoV-2 proteome sequence (GenBank MN908947.3), which bind to multiple HLA-DR molecules in a promiscuous manner and are recognized by CD4+ T lymphocytes of patients infected with the SARS-CoV-2 virus.

[0054] The epitope is selected from the group consisting of the sequences in Table 1 below:

[0055] Table 1: Potential SARS-CoV-2 CD4+ T cell epitopes

[0056]

[0057]

[0058] Furthermore, the epitope is selected from the group consisting of the sequences of Table 1, in particular selected from: SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14 and SEQ ID NO:16.

[0059] The selected epitopes are those predicted to bind to the maximum possible number of HLA-DR molecules in a "promiscuous" manner over a chosen threshold (3%) (sequences predicted to bind to at least 26 out of the 51 HLA-DR molecules available in the algorithm at a threshold of 3%, thereby selecting epitopes with a high probability of binding to HLA-DR molecules with high activity).

[0060] To obtain the final peptide sequences of Table 1, N-terminal and C-terminal flanking residues were added to increase the percentage of individuals recognizing each peptide. Combinations of synthetic peptides were designed to elicit or detect SARS-CoV-2 specific responses in more than 99% of the world's population, based on HLA frequency data from the iedb.org server. Based on in silico analysis using https: / / webs.iiitd.edu.in / raghava / propred / , it was predicted that each HLA-DR molecule would bind to at least 10 different peptides.

[0061] According to computer simulation analysis, the increase in the number of epitopes will allow each HLA-DRB1 and each individual to recognize a greater number of peptides, using a complete peptide set from SEQ ID NO: 1 to 19, reaching a minimum of 10 peptides / HLA-DRB1. The increase in the number of epitopes / individual will increase the amplitude of vaccination. The more peptides each vaccinee recognizes, the more difficult it is for mutations to jeopardize vaccine-induced protection against new mutant viruses. Complete coverage with sufficient breadth (the number of T cell epitopes recognized by each individual) is an expected emerging property of promiscuous HLA-binding epitope combinations. In a genetically heterogeneous population, each epitope alone will never be as antigenic / immunogenic as a combination of the individual epitopes.

[0062] Furthermore, the epitopes of the present invention used in combination are particularly derived from spike proteins, envelope proteins, membrane proteins, nucleocapsid proteins and other SARS-CoV-2 ORFs.

[0063] One of the advantages of the present invention is that CD4+ T cells recognize the epitope combination, which is an emerging property of a promiscuous epitope combination that can bind to multiple HLA-DR molecules. Another advantage is that it targets many non-spike viral proteins that are not susceptible to antibody-induced immune pressure and mutation.

[0064] According to the present invention, "epitope" refers to the above-mentioned epitope, its functional equivalent and its mimetic sequence.

[0065] "Functional equivalents" refer to sequences, fragments, analogs, derivatives or related substances with different structures, which perform the same function to achieve the same results. It should be understood that any changes made by those skilled in the art, if they lead to equivalent effects in an obvious way, should also be considered as part of the present invention. More specifically, functional equivalents are sequences that present at least 12 amino acid homology with the above-mentioned epitopes, and perform the same function as the epitopes, showing the same or similar results.

[0066] According to the present invention, "mimetic sequences" are understood to be non-natural amino acid sequences with modified structures such that they exhibit the same or similar functions and results as the sequences of the epitopes of the present invention.

[0067] The above epitopes are putative immunodominant SARS-CoV-2 CD4+T cell epitopes. The epitopes are selected from the entire SARS-CoV-2 proteome sequence (GenBank MN908947.3). Such synthetic peptides are designed to bind to at least 50% of the 51 HLA-DR molecules in the bioinformatics server https: / / webs.iiitd.edu.in / raghava / propred / .

[0068] In particular, the combination of 8 or more epitopes of the present invention includes the SEQ ID NOs in Table 2 below and may allow for adequate coverage. Computer simulation studies have shown that using at least the following 10 peptides, T cell responses against at least 5 peptides can be detected in all individuals.

[0069] To evaluate the ability of a combination of at least eight selected epitopes to be recognized by an individual's T lymphocytes, the epitopes (described in Table 1) were synthesized in solid phase using Fmoc chemistry and had a C-terminal amide. The synthetic peptide stock was diluted to 5 mg / mL in dimethyl sulfoxide and then subjected to an ELISPOT assay using peripheral blood mononuclear cells (PBMCs) from 98 COVID-19 convalescent patients (mild cases of the disease, not requiring hospitalization) at least two months after the onset of signs of infection to detect IFN-γ-producing cells ( Figure 8). The synthetic peptides were diluted to prepare a pool of 5 mg / mL and added to the wells (total peptide concentration of 5 μg / mL, individual concentration 0.25 μg / ml). The cryopreserved cells were cultured for 16 hours, washed and placed on ELISPOT plates in the presence of the epitope and incubated for an additional 18 hours. An ELISPOT plate was developed for the identification of spot-forming cells / interferon-γ producing cells (IFN-γSFCs), which were then counted in an automated counter (Zeiss KS ELISpot / Axioplan 2). PBMC samples from 17 seronegative control individuals obtained before the COVID-19 pandemic were used to calculate the background.

[0070] The responses in the peptide-free background wells were subtracted from the peptide-triggered responses for each of the 98 individuals tested and the results were plotted on Figure 8 The cut-off value of the reaction (103 spot forming cells (SFC) / 10 6 The ELISPOT response of 20 synthetic peptides (PBMCs) was calculated as the mean plus 3 standard deviations of the ELISPOT responses to the 20 synthetic peptides mentioned in Table 1 above. Individuals with responses above the cutoff value were considered to have T cell responses to SARS-CoV-2 peptides, indicating a recognition rate of 97%.

[0071] The combination of all epitopes of the present invention can also be used in diagnostic methods and tests for evaluating the immune response of CD4+T lymphocytes to the SARS-CoV-2 virus. For example, a diagnostic method for detecting or monitoring the response of cells to infection or vaccination allows the identification of breakthrough infections in individuals immunized with SARS-CoV-2 subunit vaccines in vivo, in vivo or in vitro. Another diagnostic method, such as an in vitro cellular immune response measurement strategy for mass diagnosis (scalable to hundreds of reactions / day) is also an embodiment of the present invention. Another example is their use in in vivo diagnosis when observing the response after administration of the peptides.

[0072] In addition, the combination of at least 8 epitopes of the present invention can be used to prepare vaccines to provide T cell help and increase its immunogenicity and protection. The vaccine may be more effective than vaccines known in the prior art because the combination of at least 8 epitopes of the present invention is recognized by T cells in most individuals, thereby covering a considerable portion of the population exposed to the virus.

[0073] Another object of the present invention is to provide a composition comprising a combination of at least 8 epitopes in SEQ ID NO: 1 to SEQ ID NO: 19. The composition further comprises a pharmaceutically acceptable carrier or vehicle.

[0074] The composition of the present invention can be in solid or liquid form. The composition can be formulated to release its components quickly or for a prolonged period of time, and can further include compounds for stimulating and / or suppressing the immune system. The composition can be prepared according to conventional methods known in the prior art.

[0075] A further object of the present invention is the use of the above composition. This includes the use of the composition in vaccine preparation, diagnostic methods and tests for evaluating the immune response of CD4+T lymphocytes to the SARS-CoV-2 virus, as described above for the combination of at least 8 epitopes described in SEQ ID NO: 1 to SEQ ID NO: 19 in Table 1 above.

[0076] The present invention also relates to a vaccine construct, wherein the vaccine construct comprises a CD4+ T cell epitope in the form of a synthetic peptide in combination with an RBD monomer or dimer.

[0077] The vaccine construct of the present invention comprises a recombinant protein composed of a single polypeptide chain, which is formed by connecting 1 to 3 novel betacoronavirus (SARS-CoV-2) spike (S) protein receptor binding domains (RBD) in series and / or a peptide string consisting of a CD4+ epitope or a CD4+ plus CD8+ T cell epitope through a linker.

[0078] The CD8+ T cell epitope is selected from the group consisting of the sequences in Table 2 below:

[0079] Table 2: SARS-CoV-2 CD8+ T cell epitopes

[0080]

[0081]

[0082] The vaccine construct of the present invention is described by the following technical scheme:

[0083] The amino acid sequence of the single polypeptide chain is represented as:

[0084] (A) RBD1-RBD2 or RBD1-RBD2-RBD3 as shown in SEQ ID NO: 54, 55, 56 and 57;

[0085] (B) RBD1-linker-peptide strings as shown in SEQ ID NOs: 58, 59 and 60;

[0086] (C) RBD1-RBD2-linker-peptide string as shown in SEQ ID NO:61, 62, 63, 64, 65, 66 and 67;

[0087] (D) RBD1-linker-RBD2 as shown in SEQ ID NOs: 68 and 69;

[0088] (E) RBD1-linker-peptide string-linker-RBD2 as shown in SEQ ID NO: 70, 71, 72, 73, 74, 75, 76 and 77,

[0089] in,

[0090] (1) The amino acid sequence of the novel betacoronavirus (SARS-CoV-2) spike (S) protein receptor binding domain (RBD) includes residues 319-537 (SEQ ID NOs: 54 to 67, SEQ ID NOs: 70 to 75) and 330-528 (SEQ ID NOs: 68, 69, 76 and 77) of the S protein;

[0091] (2) RBD1, RBD2, and RBD3 represent the amino acid sequences of the novel betacoronavirus (SARS-CoV-2) spike (S) protein receptor binding domain (RBD) from the Wuhan strain and their corresponding substitutions of the β variant (B.1.1.529, K417N, E484K, and N501Y), the γ variant (P1, K417T, E484K, and N501Y), the δ variant (B.1.617.2, L452R and T478K), and the Omicron (B.1.1.159, BA1, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, and Y505H);

[0092] (3) The novel betacoronavirus (SARS-CoV-2) spike (S) protein receptor binding domain (RBD) is connected to the peptide string in series (SEQ ID NOs: 54, 55, 56 and 57) and / or connected through a peptide linker (SEQ ID NOs: 58 to 77). Specifically, the novel betacoronavirus (SARS-CoV-2) spike (S) protein receptor binding domain (RBD) is connected to the peptide string through EAAAKEAAAKEAAAK (SEQ ID NOs: 58 to 67), KPKPKP (SEQ ID NOs: 70, 72, 74 and 75), GGGGS (SEQ ID NOs: 71 and 73) or PKPK (SEQ ID NOs: 68, 69, 76 and 77) sequences;

[0093] (4) The peptide string is composed of CD4+ and / or CD8+ T cell epitopes (see CD4+ and CD8+ T cell epitope list, SEQ ID NO: 1 to 45) connected by GPGPG linkers. Using the CD4+ and CD8+ T cell epitope list, dipeptides connected by GPGPG sequences (SEQ ID NO: 46 to 53), CD4+ T cell epitope strings 1-4 (SEQ ID NO: 54), CD4+ T cell epitope strings 5-8 (SEQ ID NO: 55), CD4+ T cell epitope string 08 (SEQ ID NO: 56), CD8+ T cell epitope string 11 (SEQ ID NO: 57) and CD4+ and CD8+ T cell epitope string 22 (SEQ ID NO: 58) were constructed.

[0094] In addition, the present invention is also directed to a vaccine construct, wherein RBD1, RBD2 and RBD3 of item (2) above represent the amino acid sequence of the receptor binding domain (RBD) of the spike (S) protein of the betacoronavirus (SARS-CoV-2) from any new variant of concern.

[0095] The vaccine construct comprises a combination of at least 8 epitopes described in Table 1 above, and one or more pharmaceutically acceptable adjuvants, vehicles, excipients, binders, carriers or preservatives.

[0096] The vaccine construct according to the present invention can be formulated in the following forms (but not limited to), including a combination of 8 or more epitopes as shown in SEQ ID NO: 1 to SEQ ID NO: 19 as described in Table 1 above:

[0097] a) combining 8 or more epitopes shown in SEQ ID NO: 1 to SEQ ID NO: 19 with an adjuvant; or

[0098] b) a recombinant or synthetic DNA or RNA construct having 8 or more neo-epitope sequences, particularly comprising another protein product; or

[0099] c) recombinant proteins or synthetic peptide constructs with new epitope sequences, in particular in combination with an adjuvant; or

[0100] d) a viral vector containing a new epitope sequence; or

[0101] e) a virus-like particle expressing an epitope as an encoded protein; or

[0102] f) Combinations of new epitopes with SARS-CoV-2 epitopes and immunogens known in the prior art, or as enhancers of such known SARS-CoV-2 immunogens.

[0103] Another object of the present invention is a method for identifying new epitopes of the combination of the present invention, which can provide high coverage of the world population ( Figure 1 ), which comprises the following steps:

[0104] a) selecting peptides from the entire SARS-CoV-2 proteome sequence, wherein the peptides bind to at least 50% of the HLA-DR molecules in the bioinformatics server https: / / webs.iiitd.edu.in / raghava / propred / ;

[0105] b) extending the selected sequence of the peptide at the N-terminus and the C-terminus;

[0106] c) World population coverage study based on the frequencies of HLA molecules predicted to bind to peptides from the iedb.org website;

[0107] d) synthesizing the corresponding peptide;

[0108] e) Confirm and test SARS-CoV-2-specific responses in susceptible individuals who had mild COVID-19 illness (not hospitalized) and recovered well.

[0109] In silico population coverage analysis was also performed for selected combinations of 8 and 11 CD4+ peptides present in some of the structures mentioned in this article. The IEDB Population Coverage, also at iedb.org, evaluated the world population coverage of 11 selected CD4+ peptide combinations (that were part of some of the above structures) and showed that 90.6% of the world population could recognize at least one epitope, with an average of 9.8 HLA / epitope combinations recognized per individual. World population coverage for a combination of 8 CD4+ T-cell epitopes (that were part of some of the above structures) would also cover 90.6% of the population, with an average of 9.5 HLA / epitope combinations recognized per individual. World population coverage for a combination of 8 CD4+ T-cell epitopes (that were part of some of the above structures) would also cover 90.6% of the population, with an average of 6.3 HLA / epitope combinations recognized per individual. In summary, these in silico results show that subsets of 8 or 11 CD4+ epitopes achieve high population coverage, with a large number of peptides capable of binding per HLA molecule.

[0110] The following examples are illustrative in order to provide a clearer and more consistent understanding of the present invention but are not intended to limit the scope thereof.

[0111] Example

[0112] Example 1

[0113] T cell responses to selected CD4+ and CD8+ T cell epitopes in patients recovering from SARS-CoV-2

[0114] To assess cellular responses to predicted T-cell epitopes, samples from 110 convalescent participants collected approximately 40 days after infection were used. Blood was processed to obtain peripheral blood mononuclear cells (PBMCs), which were cryopreserved in liquid nitrogen until use.

[0115] After in silico analysis of the SARS-CoV-2 sequence and selection of CD4+ T cell epitopes that were likely to be more promiscuous, the selected peptides were synthesized. In total, the synthesis included 19 peptides from CD4+ T cells and 26 peptides from CD8+ T cells. The synthetic peptides were used to stimulate PBMCs for 24 h and were analyzed by ELISPOT to assess IFN-g production.

[0116] The analysis showed that synthetic peptides corresponding to CD4+ T-cell epitopes had adequate immune coverage in convalescent subjects, inducing T lymphocyte responses in 92% of the samples tested ( Figure 8 ).

[0117] Then, to analyze the overall immunodominance of CD4+ T cell epitopes, PBMCs were stimulated with each peptide alone. Again, the magnitude of the response varied between subjects, however, each peptide alone induced IFN-g-producing T cells in 60%-80% of the patients tested. Each patient's T cells recognized an average of 14 of the 19 CD4+ T cell peptides, or 74% of the epitopes tested, and 93% of the patients recognized at least one CD4+ T cell epitope (data not shown), indicating the promiscuity of HLA class II binding and T cell responses.

[0118] A similar analysis of T cell recognition of 26 CD8+ T cell epitopes was performed in the same convalescent cohort. It was observed that 26 synthetic peptides corresponding to CD8+ T cell epitopes had adequate immune coverage in convalescent subjects, inducing T lymphocyte responses in 91% of the samples tested ( Fig. 9 ).

[0119] To analyze the overall immunodominance of CD8+ T cell epitopes, PBMCs were stimulated individually with each CD8+ peptide epitope. The magnitude of the response varied between subjects, however, each patient's T cells recognized an average of 20 of the 26 CD4+ T cell peptides, or 77% of the epitopes tested, and 95% of patients recognized at least one CD4+ T cell epitope (data not shown), indicating the surprising promiscuity of HLA class I binding and T cell responses.

[0120] The results showed that peptides predicted by computer simulations were highly recognized by cells from convalescent patients and that there was no immunodominant pattern of responses to peptides derived from different regions of the virus.

[0121] Example 2 - Humoral responses to vaccines encoding RBD and synthetic peptides: Induction of specific antibodies

[0122] To identify the best vaccine candidate and immunization strategy, C57BL / 6 mice were immunized as described in Table 3 below. The animals used were obtained from the Center for the Development of Experimental Models in Medicine and Biology (CEDEME) and were housed in animal vivariums at the Discipline of Immunology (DMIP / UNIFESP), pathogen-free, with a controlled light-dark cycle (12:12), and with free access to water and food. This project had been previously approved by the Ethical Committee for the Use of Animals (CEUA-UNIFESP) under number 4813280820.

[0123] Table 3: Immunization schemes for humoral and cellular immune responses

[0124]

[0125] Animals were immunized with 5 μg of 5 μg Wuhan dimeric RBD protein or 5 μg Wuhan dimeric RBD protein plus 50 μg of 8 synthetic dipeptides (as shown in SEQ ID NO: 46 to 53), each dipeptide containing one CD4+ T cell epitope and one CD8+ T cell epitope (as shown in Table 4 below), and injected subcutaneously (SC) with 100 μL in the presence of AS03 adjuvant (1:1 v / v), with an interval of 15 days between each injection. The control group received ASO3 adjuvant only by SC route.

[0126] Table 4. 8 synthetic dipeptides, each containing one CD4+ T cell epitope and one CD8+ T cell epitope.

[0127]

[0128]

[0129] To analyze the humoral immune response, animal blood was collected 14 days after each administration, and the titer of dimer-specific RBD antibodies was determined by ELISA. To this end, an ELISA plate (High binding, Costar) was used, and 250 ng of the dimeric RBD recombinant protein produced and characterized as described above was added to each well. After incubation for 16 to 18 hours at room temperature, the plate was washed with 0.02% PBS-Tween 20 (PBS-T0.02) and blocked (PBS-T0.02 / 1% BSA) for 1 hour at room temperature. After incubation for 2 hours with serial dilutions of immune mouse serum, the contents of the wells were discarded and the plates were washed with PBS-T 0.02. A secondary antibody (anti-mouse IgG-KPL linked to peroxidase) diluted in PBS-T0.02 / BSA 1% was added at a ratio of 1:10,000 and incubated for another 2 hours at room temperature. After washing three times with PBS-T 0.02, the plates were developed with a solution containing OPD (Sigma) dissolved in 0.2M NaH2PO4 and 0.1M citric acid (pH 4.7) plus 10 μL 30% H2O2. After 15 minutes, the reaction was terminated with 50 μL 4N H2SO4 solution. The plates were then analyzed in a 96-well plate reader at a wavelength of 492 nm (PerkinElmer).

[0130] Analysis of serum antibody production showed comparable IgG production in animals that received either RBD or RBD + 8 synthetic peptides encoding SARS-CoV-2 CD4+ and CD8+ T cell epitopes ( Fig.10 ).

[0131] Example 3 - Cellular immune responses to vaccines encoding SARS-CoV-2 RBD and selected SARS-CoV-2 synthetic peptides: Induction of strong peptide-specific T cell responses

[0132] In addition to humoral immune responses, cellular immune responses also play an important role in preventing SARS-CoV-2. The differentiation of recombinant SARS-CoV-2 RBD antigen-specific T lymphocytes in mice immunized with 5 μg of Wuhan dimer RBD protein or 5 μg of Wuhan dimer RBD protein plus 50 μg of 8 synthetic dipeptide pools (as shown in SEQ ID NO: 46 to 53) (each dipeptide contains one CD4+ T cell epitope and one CD8+ T cell epitope, see Table 4 in Example 2 above) was evaluated.

[0133] The overview of IFN-γ producing cells in the spleen of immune mice was analyzed by ELIspot. Therefore, after euthanasia, the spleen of each animal was collected by surgical materials in laminar flow. 10ml of RPMI culture medium (Gibco) was used to obtain and clean cells by centrifugation. Then, cells were processed with ACK hemolysis buffer (0.15M NH4Cl, 1mM KHCO3, 0.1mM Na2EDTA), and then washed twice with 10ml RPMI culture medium. Finally, cells were resuspended in 1ml R10 culture medium (RPMI culture medium supplemented, containing 10% fetal bovine serum-Gibco).

[0134] According to the manufacturer's instructions, ELISpot assay was performed using mouse IFN-γ ELISpot kit (BD Biosciences). In brief, capture antibody (purified IFN-γ anti-mouse) was added to plate (Millipore Multi-Screen IP-MAIPS 4510) at a concentration of 5 μg / mL, and the final volume was 100 μL, and the plate was stored overnight at 4 ° C. Then, wells were washed with PBS and blocked at room temperature for 2 hours with RPMI culture medium containing 10% fetal bovine serum (R10). After this period, stimulants (each single dipeptide, 5 μg / mL) and cell suspension were added. Plates were incubated overnight at 37 ° C in an oven containing 5% CO2. Subsequently, plates were washed with deionized water and PBS-0.05% Tween20 (PBS-T). Detection antibody (biotinylated anti-IFN-γ) was diluted in PBS-10% FBS and added to wells at a final concentration of 2 μg / mL, and plates were incubated at room temperature for 2 hours. After washing the wells 3 times with PBS-T, the enzyme conjugate (streptavidin-peroxidase) was diluted in PBS-10% FBS and added to the wells (100 μL / well), followed by another 1 hour incubation step at room temperature. For development, the wells were washed 4 times with PBS-T and then washed 2 times with 1X PBS. 100 μL AEC (3-amino-9-ethylcarbazole-BD) solution was then added to each well and spot formation was monitored. The plate was washed 5 times with deionized water to terminate the reaction. UFS (spot forming units) were counted on the reader AID ELISpot reader system (Autoimmun Diagnostika GmbH, Germany).

[0135] Fig.11 The cellular immune responses of mice immunized with Wuhan dimeric RBD protein or dimeric RBD protein + 8 dipeptides to each individual dipeptide are shown. As can be seen, all peptides triggered a strong immune response, exceeding 1,000 SFU / 10 in the group co-immunized with the synthetic peptide. 6This indicates that the selected SARS-CoV-2 peptides are highly immunogenic.

[0136] Further results showed that when using dimeric RBD recombinant protein + 8 dipeptides as shown in SEQ ID NO: 46 to 53, there were additional non-homologous effects in the cellular immune response, such as Fig.12 as shown in .

[0137] It can be determined that the increase in cellular immune response in the immunization group with adjuvant+RBD+dipeptide is directly caused by the additional immunity caused by the dipeptides as shown in SEQ ID NOs: 46 to 53, which have no common epitopes with the RBD protein.

[0138] References:

[0139] DAI, Lianpan et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell, v.182, n.3, p.722-733.e11, ago.2020.

[0140] SCHMIDT,Fabian et al.Measuring SARS-CoV-2 neutralizing antibodyactivity using pseudotyped and chimeric viruses.Journal of ExperimentalMedicine,v.217,n.11,2nov.2020.

[0141] YAN, Jian et al.Enhanced Cellular Immune Responses Elicited by anEngineered HIV-1Subtype B Consensus-based Envelope DNA Vaccine.MolecularTherapy,v.15,n.2,p.411–421,fev.2007.

Claims

1. An epitope combination, wherein: The combination comprises at least 8 T cell epitopes from SARS-CoV-2.

2. The epitope combination according to claim 1, wherein The epitope is widely recognized by CD4+ T lymphocytes.

3. The epitope combination according to claim 1 to 2, wherein: The T cell epitope is selected from SEQ ID NO: 1 to SEQ ID NO:

19.

4. The epitope combination according to claim 3, wherein: The T cell epitope is selected from the group consisting of: SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14 and SEQ ID NO:

16.

5. A vaccine construct comprising the amino acid sequence of a single polypeptide chain as shown below (A) RBD1-RBD2 or RBD1-RBD2-RBD3 as shown in SEQ ID NO: 54, 55, 56 and 57; (B) RBD1-linker-peptide strings as shown in SEQ ID NOs: 58, 59 and 60; (C) RBD1-RBD2-linker-peptide string as shown in SEQ ID NO:61, 62, 63, 64, 65, 66 and 67; (D) RBD1-linker-RBD2 as shown in SEQ ID NOs: 68 and 69; (E) RBD1-linker-peptide string-linker-RBD2 as shown in SEQ ID NO: 70, 71, 72, 73, 74, 75, 76 and 77, in, (1) The amino acid sequence of the novel betacoronavirus (SARS-CoV-2) spike (S) protein receptor binding domain (RBD) includes residues 319-537 (SEQ ID NOs: 54 to 67, SEQ ID NOs: 70 to 75) and 330-528 (SEQ ID NOs: 68, 69, 76 and 77) of the S protein; (2) RBD1, RBD2, and RBD3 represent the amino acid sequences of the novel betacoronavirus (SARS-CoV-2) spike (S) protein receptor binding domain (RBD) from the Wuhan strain and their corresponding substitutions of the β variant (B.1.1.529, K417N, E484K, and N501Y), the γ variant (P1, K417T, E484K, and N501Y), the δ variant (B.1.617.2, L452R and T478K), and the Omicron (B.1.1.159, BA1, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, and Y505H); (3) the novel betacoronavirus (SARS-CoV-2) spike (S) protein receptor binding domain (RBD) is linked to the peptide string in tandem (SEQ ID NOs: 54, 55, 56, and 57) and / or via a peptide linker (SEQ ID NOs: 58 to 77); (4) The peptide string is constructed by connecting CD4+ and / or CD8+ T cell epitopes (see the CD4+ and CD8+ T cell epitope list, SEQ ID NOs: 1 to 45) via a GPGPG linker; wherein, the dipeptides (SEQ ID NOs: 46 to 53), CD4+ T cell epitope strings 1-4 (SEQ ID NO: 54), CD4+ T cell epitope strings 5-8 (SEQ ID NO: 55), CD4+ T cell epitope string 08 (SEQ ID NO: 56), CD8+ T cell epitope string 11 (SEQ ID NO: 57) and CD4+ and CD8+ T cell epitope string 22 (SEQ ID NO: 58) are constructed from the CD4+ and CD8+ T cell epitope list.

6. The vaccine construct according to claim 5, wherein The novel betacoronavirus (SARS-CoV-2) spike (S) protein receptor binding domain (RBD) and the peptide string are connected by EAAAKEAAAKEAAAK (SEQ ID NOs: 58 to 67), KPKPKP (SEQ ID NOs: 70, 72, 74 and 75), GGGGS (SEQ ID NOs: 71 and 73) or PKPK (SEQ ID NOs: 68, 69, 76 and 77) sequences.

7. The vaccine construct according to claim 5, wherein RBD1, RBD2 and RBD3 of item (2) represent the amino acid sequence of the receptor binding domain (RBD) of the spike (S) protein of the betacoronavirus (SARS-CoV-2) from any new variant of concern.

8. A vaccine construct comprising a CD4+ T cell epitope in the form of a synthetic peptide in combination with an RBD monomer or dimer.

9. The vaccine construct according to claim 6, wherein The peptides of the combination are shown in SEQ ID NOs: 46 to 53.

10. A vaccine construct, wherein It includes: a) combining 8 or more epitopes shown in SEQ ID NO: 1 to SEQ ID NO: 19 with an adjuvant; or b) a recombinant or synthetic DNA or RNA construct having 8 or more neo-epitope sequences, particularly comprising another protein product; or c) recombinant proteins or synthetic peptide constructs with new epitope sequences, in particular in combination with an adjuvant; or d) a viral vector containing a new epitope sequence; or e) a virus-like particle expressing an epitope as an encoded protein; or f) Combinations of new epitopes with SARS-CoV-2 epitopes and immunogens known in the prior art, or as enhancers of such known SARS-CoV-2 immunogens.

11. The vaccine construct according to claims 5 to 10, wherein The vaccine construct further comprises one or more pharmaceutically acceptable adjuvants, vehicles, excipients, binders, carriers or preservatives.

12. A method of inducing an immune response comprising administering a vaccine construct as defined in any one of claims 5 to 11.

13. A method for identifying SARS-CoV-2 T cell epitopes for a vaccine, comprising the following steps: a. Select peptides from the entire SARS-CoV-2 proteome sequence, where the peptides bind to at least 50% of the HLA-DR molecules in the bioinformatics server https: / / webs.iiitd.edu.in / raghava / propred / ; b. extending the selected peptide sequence at the N-terminus and C-terminus; c. World population coverage study based on the frequencies of HLA molecules predicted to bind to peptides from the iedb.org website; d. synthesizing the corresponding peptide; e. SARS-CoV-2-specific responses in susceptible individuals who have had mild COVID-19 illness (not hospitalized) and have recovered well, confirmed by testing.

14. Use of a combination as defined in claims 1 to 4 for the production of a vaccine construct as claimed in any one of claims 5 to 11.

Citation Information

Cited By

  • HLA-B restrictive SARS-CoV-2 lymphocyte antigen epitope peptide and application thereof

    CN119798385A